This enhancement was found to be due to mediation by VEGF-C induced CCL21 associated with tumor infiltration of naïve T cells before immunotherapy as CCR7 blockade reversed the potentiating effects of VEGF-C. The gene discussed is CCR7; the disease is neoplasm.